Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer
19 mai 2011 08h02 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of a Phase 2 clinical trial of retaspimycin hydrochloride (HCl), also...
Infinity Announces Clinical Data to be Presented at ASCO
19 mai 2011 07h58 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 19, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that clinical data for IPI-926, its novel Smoothened antagonist, and retaspimycin...
Infinity Reports First Quarter 2011 Financial Results
10 mai 2011 16h00 HE
|
Infinity Pharmaceuticals, Inc.
— Reaffirms 2011 Financial Guidance and Provides Additional Details —
— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
Infinity Announces the Date of Its First Quarter 2011 Financial Results Conference Call and Webcast
03 mai 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, May 10, 2011 at 4:30 p.m. ET. During the call, management will...
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
11 avr. 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 11, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the appointment of Joshua D. Hamermesh as vice president, business and corporate...
Infinity Pharmaceuticals to Present at BioCentury Future Leaders Conference
07 avr. 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at BioCentury's 18th Annual Future Leaders in the Biotech Industry Conference on...
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
03 avr. 2011 13h36 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
Infinity to Present New Preclinical Data on IPI-926, a Novel Smoothened Antagonist Targeting the Hedgehog Pathway, at Upcoming AACR Meeting
23 mars 2011 08h01 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 23, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that the company will present new preclinical data supporting ongoing development of...
Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results
15 mars 2011 16h00 HE
|
Infinity Pharmaceuticals, Inc.
IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum
Cash Runway Into 2014 Enables Advancement of Product Candidates to
Key Inflection Points
Company Changes Accounting...
Infinity Announces the Date of Its Fourth Quarter 2010 Financial Results Conference Call and Webcast
08 mars 2011 08h30 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 8, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, March 15, 2011 at 4:30 p.m. ET. During the call, management...